Bluejay Diagnostics Completes Exercise of All Prefunded Warrants, Clarifies Capital Structure

summarizeSummary

Bluejay Diagnostics announced the full exercise of all prefunded warrants from its October 2025 private placement, providing cash and clarifying its outstanding share count and remaining warrant obligations.

check_boxKey Events

• Prefunded Warrants Fully Exercised

  All prefunded warrants issued in the October 2025 private placement have been fully exercised as of February 19, 2026, eliminating this class of outstanding warrants and providing cash to the company.

• Capital Structure Clarified

  The company now has approximately 972,000 shares of common stock outstanding. Additionally, 1.5 million cash exercisable warrants remain outstanding with a strike price of $7.00 or greater per share.

• Warning on 13G Filings

  Bluejay Diagnostics noted that recent Schedule 13G filings may not reflect the 1-for-4 reverse stock split effective January 29, 2026, potentially overstating beneficial ownership amounts.

auto_awesomeAnalysis

This filing provides important clarity on Bluejay Diagnostics' capital structure. The full exercise of all prefunded warrants means the company has received the associated cash, improving its liquidity. While this results in an increase in outstanding shares, it resolves a prior financing obligation. The disclosure of approximately 972,000 shares outstanding and 1.5 million remaining warrants with a high exercise price ($7.00+) provides transparency. The warning about outdated Schedule 13G filings is crucial for investors to accurately assess beneficial ownership post-reverse stock split.